Aclasta: Extension study data

Data from 1,233 women aged 68 years and older in a 3-year, placebo-controlled extension of the double-blind, international Phase III HORIZON trial showed that patients who received 5 mg once-yearly Aclasta for 6 years had a 52% reduced risk of new morphometric spine fractures vs. patients who stopped treatment with Aclasta at 3 years (p=0.04). Additionally, BMD decreased in patients who stopped Aclasta treatment at 3 years, but remained above baseline levels with no evidence of accelerated bone loss. Data were presented at the American Society for Bone and Mineral Research meeting in Toronto. ...